Obicetrapib

NewAmsterdam Pharma Company N.V. (NAMS) focuses on developing therapies for metabolic diseases, including obicetrapib for cardiovascular and Alzheimer's diseases. With a market cap of 2.671B, it reported a -2.35% change at close, trading at 24.95 USD. The company, based in the Netherlands, has 62 full-time employees and is in the biotechnology sector.

NewAmsterdam Pharma updates on obicetrapib's clinical development, targeting LDL-C lowering therapies for cardiovascular disease patients. Plans include Phase 3 trial data announcements, studies on obicetrapib's effects, and commercial manufacturing readiness for potential U.S. and European launches.

NewAmsterdam Pharma updates on obicetrapib's clinical development, highlighting 2024 achievements including positive Phase 3 trial results. Plans for 2025 include additional data presentations, regulatory filings, and commercial readiness, supported by a strong financial position. Obicetrapib aims to address unmet needs in cardiovascular disease treatment.

NewAmsterdam Pharma reported 2024 successes with Phase 3 trials for obicetrapib, targeting LDL-C reduction and cardiovascular risk. Plans include advancing trials in 2025 and preparing for U.S. and Europe launches, backed by solid finances. Focused on oral, non-statin treatments for high LDL-C patients.

NewAmsterdam Pharma updates on obicetrapib's clinical development, highlighting 2025 data presentations from BROADWAY, BROOKLYN, TANDEM, and Phase 2 VINCENT trials. Plans include EMA submission, manufacturing capacity establishment, and inventory build-out. Ended 2024 with $835M cash balance. Obicetrapib aims to lower LDL-C in CVD patients inadequately served by current therapies.

Rakovina Therapeutics Inc. unveils AI-designed cancer drug candidates. Biomea Fusion Inc. introduces a groundbreaking diabetes treatment. Sensei Biotherapeutics Inc. updates on its cancer drug. BioLargo Inc. is highlighted for investment. AI aids in medical diagnostics. CytoSorbents Corp. reports revenue growth. Quince Therapeutics Inc. eyes a transformative year. Corvus Pharmaceuticals Inc. launches a pivotal cancer trial. Veru Inc. begins a new clinical trial. MetaVia Inc. explores weight-loss drugs. NewAmsterdam Pharma's drug hailed as revolutionary. Gain Therapeutics Inc. advances Parkinson's treatment. MeiraGTx Holdings Plc receives FDA expedited review. Treatment.com AI Inc. poised for industry transformation. Rakovina Therapeutics Inc. leverages AI in drug development. Annexon Inc. supports BLA package with new data. Premier Health of America Inc. faces Quebec law impact.

NewAmsterdam Pharma's obicetrapib hailed as a transformative drug for cardiovascular disease, with a Buy rating and $48 target price.

Ed Arce, a managing director at H.C. Wainwright & Co., specializes in biopharmaceuticals and specialty pharmaceuticals. NewAmsterdam Pharma's obicetrapib is hailed as a groundbreaking drug for cardiovascular disease.